« Return to News | Drug Sponsors

Cephalon rejects buyout, Valeant remains committed

Wednesday, April 6, 2011 11:52 AM

U.S.-based Cephalon has rejected Canadian-based Valeant Pharmaceuticals International's takeover bid, saying that the $5.7 billion offer, or $73.00 per share, is not in the best interests of shareholders, according to Pharma Times.

Cephalon states they have "one of the broadest pipelines in the industry, with 10 late-stage product candidates targeted at novel and 'best-in-class' therapeutics." This includes six indications "with blockbuster potential which are projected to begin launching in the next three years" and these programs "represent tremendous value that is not reflected in Valeant's current proposal."

Valeant chief executive Michael Pearson responded by saying that "while we are disappointed with the response from Cephalon's board, we remain committed to our process." This includes "trying to find a modest amount of additional value if Cephalon engages with us and allows us to conduct due diligence, which we believe would take only 2-3 weeks."

Pearson also claimed to have received "positive feedback from many of the largest stockholders of Cephalon" and "we stand ready to quickly commence and close our transaction as proposed, unless Cephalon stockholders do not support our offer, in which case we will focus our attention on other opportunities to invest our capital."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.